bupropion and Blood Pressure, High studies

Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.

Research Excerpts

Excerpt	Relevance	Reference
"CONTRAVE Obesity Research-II (COR-II) was a double-blind, placebo-controlled study of 1,496 obese (BMI 30-45 kg/m(2) ) or overweight (27-45 kg/m(2) with dyslipidemia and/or hypertension) participants randomized 2:1 to combined naltrexone sustained-release (SR) (32 mg/day) plus bupropion SR (360 mg/day) (NB32) or placebo for up to 56 weeks."	9.17	A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). ( Apovian, CM; Aronne, L; Burns, C; Dunayevich, E; Kim, D; Rubino, D; Still, C; Wyatt, H, 2013)
"The effects of bupropion on blood pressure and heart rate were evaluated in a double-blind, placebo-controlled study of community volunteers with untreated mild (stage 1) hypertension (systolic blood pressure [SBP], 140-159 mm Hg, and/or diastolic blood pressure, 90-99 mm Hg)."	9.13	A randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertension. ( Fleck, RJ; Haight, BR; Hunt, T; Johnson, MC; Krishen, A; Modell, JG; Thase, ME, 2008)
"Bupropion is an increasingly prescribed agent to aid in smoking cessation."	7.72	Severe sinus bradycardia after initiation of bupropion therapy: a probable drug-drug interaction with metoprolol. ( Greene, JL; McCollum, DL; McGuire, DK, 2004)
"CONTRAVE Obesity Research-II (COR-II) was a double-blind, placebo-controlled study of 1,496 obese (BMI 30-45 kg/m(2) ) or overweight (27-45 kg/m(2) with dyslipidemia and/or hypertension) participants randomized 2:1 to combined naltrexone sustained-release (SR) (32 mg/day) plus bupropion SR (360 mg/day) (NB32) or placebo for up to 56 weeks."	5.17	A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). ( Apovian, CM; Aronne, L; Burns, C; Dunayevich, E; Kim, D; Rubino, D; Still, C; Wyatt, H, 2013)
"The effects of bupropion on blood pressure and heart rate were evaluated in a double-blind, placebo-controlled study of community volunteers with untreated mild (stage 1) hypertension (systolic blood pressure [SBP], 140-159 mm Hg, and/or diastolic blood pressure, 90-99 mm Hg)."	5.13	A randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertension. ( Fleck, RJ; Haight, BR; Hunt, T; Johnson, MC; Krishen, A; Modell, JG; Thase, ME, 2008)
"In people with elevated blood pressure, orlistat, phentermine/topiramate and naltrexone/bupropion reduced body weight; the magnitude of the effect was greatest with phentermine/topiramate."	5.12	Long-term effects of weight-reducing drugs in people with hypertension. ( Berghold, A; Horvath, K; Jeitler, K; Krenn, C; Semlitsch, T; Siebenhofer, A; Winterholer, S, 2021)
"Here we report a case of bupropion abuse in a 79-year-old gentleman with a history of alcohol and amphetamine use disorders, resulting in hypertension and hypomanic symptoms."	3.81	Bupropion abuse resulting in hypomania in a geriatric amphetamine user: A case report. ( Rostas, A; Wolf, U, 2015)
"The incidence of seizures after unintentional bupropion ingestion in children aged < 6 years has been reported as 0."	3.76	Unintentional ingestion of bupropion in children. ( Baker, SD; Beuhler, M; Bosse, GM; Gray, T; Spiller, HA, 2010)
"Bupropion is an increasingly prescribed agent to aid in smoking cessation."	3.72	Severe sinus bradycardia after initiation of bupropion therapy: a probable drug-drug interaction with metoprolol. ( Greene, JL; McCollum, DL; McGuire, DK, 2004)
"Bupropion SR has an excellent adverse effect profile, although a risk exists for serious adverse effects such as seizures."	2.42	Bupropion sustained release for treatment of tobacco dependence. ( Ebbert, JO; Hays, JT, 2003)

Research

Studies (17)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Body Weight- Mean Percent Change From Baseline to Week 56

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (5.88)	18.2507
2000's	6 (35.29)	29.6817
2010's	9 (52.94)	24.3611
2020's	1 (5.88)	2.80

Authors	Studies
Siebenhofer, A	1
Winterholer, S	1
Jeitler, K	1
Horvath, K	1
Berghold, A	1
Krenn, C	1
Semlitsch, T	1
Apovian, CM	1
Aronne, L	1
Rubino, D	1
Still, C	1
Wyatt, H	1
Burns, C	1
Kim, D	1
Dunayevich, E	1
Katsi, VK	1
Marketou, M	1
Vamvakou, G	1
Makris, T	1
Tousoulis, D	1
Stefanadis, CI	1
Vardas, P	1
Kallikazaros, IE	1
Sharma, A	1
Thakar, S	1
Lavie, CJ	1
Garg, J	1
Krishnamoorthy, P	1
Sochor, O	1
Arbab-Zadeh, A	1
Lichstein, E	1
Fujioka, K	1
McGinty, EE	1
Baller, J	1
Azrin, ST	1
Juliano-Bult, D	1
Daumit, GL	1
Rostas, A	1
Wolf, U	1
Silva, AP	1
Scholz, J	1
Abe, TO	1
Pinheiro, GG	1
Gaya, PV	1
Pereira, AC	1
Santos, PC	1
Hong, K	1
Herrmann, K	1
Dybala, C	1
Halseth, AE	1
Lam, H	1
Foreyt, JP	1
Spiller, HA	1
Bosse, GM	1
Beuhler, M	1
Gray, T	1
Baker, SD	1
Applebee, GA	1
Attarian, HP	1
Schenck, CH	1
Hays, JT	1
Ebbert, JO	1
McCollum, DL	1
Greene, JL	1
McGuire, DK	1
Marcucci, C	1
Sandson, NB	1
Dunlap, JA	1
Wilens, TE	1
Hammerness, PG	1
Biederman, J	1
Kwon, A	1
Spencer, TJ	1
Clark, S	1
Scott, M	1
Podolski, A	1
Ditterline, JW	1
Morris, MC	1
Moore, H	1
Thase, ME	1
Haight, BR	1
Johnson, MC	1
Hunt, T	1
Krishen, A	1
Fleck, RJ	1
Modell, JG	1
Roose, SP	1
Dalack, GW	1
Glassman, AH	1
Woodring, S	1
Walsh, BT	1
Giardina, EG	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Naltrexone Sustained Release (SR)/Bupropion Sustained Release (SR) and Placebo in Obese Subjects[NCT00567255]	Phase 3	1,496 participants (Actual)	Interventional	2007-12-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"Beginning at Week 28 through Week 44, NB32-treated subjects who failed to achieve or maintain at least 5% body weight loss from baseline were re-randomized (1:1 ratio) to continue NB32 or begin treatment with a higher dose of naltrexone SR - naltrexone SR 48 mg/bupropion SR 360 mg (referred to as NB48) (daily dose of bupropion SR was 360 mg for NB32 and NB48).The analysis of NB32 vs. placebo at Week 56 was completed using a weighted analysis. This analysis was referred to as the weighted LOCF analysis.~Subjects treated with NB32 who were re-randomized to NB48 were not included. Subjects re-randomized to NB32 were double-weighted and subjects who were not re-randomized were single-weighted. Subjects in the placebo group were single-weighted. The double weighting analysis restored the influence of poor performers at Weeks 28 to 44 in the NB32 group without including any data from the higher dose group (NB48)." (NCT00567255)
Timeframe: Baseline, 56 weeks

Body Weight- Proportion of Subjects With ≥10% Decrease From Baseline to Week 28

Body Weight- Proportion of Subjects With ≥5% Decrease From Baseline to Week 56

Intervention	percentage of body weight (Least Squares Mean)
NB32	-6.40
Placebo	-1.23

Intervention	percentage of participants (Number)
NB32	27.27
Placebo	7.02

Change in Diastolic Blood Pressure

Change in Fasting Blood Glucose Levels

Change in Fasting HDL Cholesterol Levels

Change in Fasting Insulin Levels, Using Log-transformed Data

Change in Fasting LDL Cholesterol Levels

Change in Fasting Triglycerides Levels, Using Log-transformed Data

Change in Food Craving Inventory Carbohydrates Subscale Score

Intervention	percentage of participants (Number)
NB32	50.48
Placebo	17.11

Intervention	mm Hg (Least Squares Mean)
NB32	0.20
Placebo	-0.67

Intervention	mg/dL (Least Squares Mean)
NB32	-2.11
Placebo	-1.73

Intervention	mg/dL (Least Squares Mean)
NB32	1.19
Placebo	-1.40

Intervention	percent change (Least Squares Mean)
NB32	-14.14
Placebo	-0.50

Intervention	mg/dL (Least Squares Mean)
NB32	-4.36
Placebo	0.00

Intervention	percent change (Least Squares Mean)
NB32	-7.32
Placebo	-1.36

The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00567255)
Timeframe: Baseline, 28 weeks

Change in Food Craving Inventory Sweets Subscale Score

Intervention	units on a scale (Least Squares Mean)
NB32	-2.68
Placebo	-2.20

The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00567255)
Timeframe: Baseline, 28 weeks

Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data

Change in HOMA-IR Levels, Using Log-transformed Data

Intervention	units on a scale (Least Squares Mean)
NB32	-3.20
Placebo	-3.18

Intervention	percent change (Least Squares Mean)
NB32	-9.38
Placebo	-1.14

HOMA-IR= Homeostasis Model Assessment-Insulin Resistance (NCT00567255)
Timeframe: Baseline, 28 weeks

Change in IDS-SR Total Score

Intervention	percent change (Least Squares Mean)
NB32	-16.44
Placebo	-4.15

IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression. (NCT00567255)
Timeframe: Baseline, 28 weeks

Change in IWQOL-Lite Total Scores

Intervention	units on a scale (Least Squares Mean)
NB32	-0.23
Placebo	-0.28

IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment (NCT00567255)
Timeframe: Baseline, 28 weeks

Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire

Intervention	units on a scale (Least Squares Mean)
NB32	9.94
Placebo	6.17

Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult (NCT00567255)
Timeframe: Baseline, 28 weeks

Article	Year
Long-term effects of weight-reducing drugs in people with hypertension. The Cochrane database of systematic reviews, 2021, 01-17, Volume: 1 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Bias; Blood Pressure; Body Weight; Bupropion; Diet	2021
Novel antidepressant drugs, arterial hypertension and cardiovascular disease. Recent patents on cardiovascular drug discovery, 2013, Volume: 8, Issue:3 Topics: Animals; Antidepressive Agents; Bupropion; Cardiovascular Diseases; Cardiovascular System; Cyclohexa	2013
Cardiovascular adverse events associated with smoking-cessation pharmacotherapies. Current cardiology reports, 2015, Volume: 17, Issue:1 Topics: Benzazepines; Bupropion; Chest Pain; Dose-Response Relationship, Drug; Humans; Hypertension; Nicotin	2015
Current and emerging medications for overweight or obesity in people with comorbidities. Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:11 Topics: Anti-Obesity Agents; Bupropion; Cinnamates; Comorbidity; Cyclohexanes; Diabetes Mellitus; Dyslipidem	2015
Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review. Schizophrenia bulletin, 2016, Volume: 42, Issue:1 Topics: Behavior Therapy; Bipolar Disorder; Bupropion; Cardiovascular Diseases; Diabetes Mellitus; Dopamine	2016
Bupropion sustained release for treatment of tobacco dependence. Mayo Clinic proceedings, 2003, Volume: 78, Issue:8 Topics: Antidepressive Agents, Second-Generation; Bupropion; Drug Hypersensitivity; Humans; Hypertension; Pa	2003

Article	Year
A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring, Md.), 2013, Volume: 21, Issue:5 Topics: Adult; Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Delayed-Action Preparations; Dopamin	2013
Naltrexone/Bupropion extended release-induced weight loss is independent of nausea in subjects without diabetes. Clinical obesity, 2016, Volume: 6, Issue:5 Topics: Adult; Anti-Obesity Agents; Body Mass Index; Bupropion; Combined Modality Therapy; Delayed-Action Pr	2016
Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. The Journal of clinical psychiatry, 2005, Volume: 66, Issue:2 Topics: Adult; Amphetamines; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Blood Pre	2005
A randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertension. Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:3 Topics: Adult; Antidepressive Agents, Second-Generation; Blood Pressure; Blood Pressure Monitors; Bupropion;	2008

Article	Year
Bupropion abuse resulting in hypomania in a geriatric amphetamine user: A case report. The American journal on addictions, 2015, Volume: 24, Issue:8 Topics: Aged; Amphetamine-Related Disorders; Antidepressive Agents, Second-Generation; Bipolar Disorder; Bup	2015
Influence of smoking cessation drugs on blood pressure and heart rate in patients with cardiovascular disease or high risk score: real life setting. BMC cardiovascular disorders, 2016, Jan-05, Volume: 16 Topics: Adult; Aged; Blood Pressure; Brazil; Bupropion; Cardiovascular Diseases; Comorbidity; Coronary Arter	2016
Unintentional ingestion of bupropion in children. The Journal of emergency medicine, 2010, Volume: 38, Issue:3 Topics: Bupropion; Child, Preschool; Dopamine Uptake Inhibitors; Female; Hallucinations; Humans; Hypertensio	2010
An angry bed partner. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2009, Oct-15, Volume: 5, Issue:5 Topics: Anger; Antidepressive Agents, Second-Generation; Bupropion; Coronary Artery Disease; Depressive Diso	2009
Severe sinus bradycardia after initiation of bupropion therapy: a probable drug-drug interaction with metoprolol. Cardiovascular drugs and therapy, 2004, Volume: 18, Issue:4 Topics: Adrenergic beta-Antagonists; Arrhythmia, Sinus; Bradycardia; Bupropion; Dopamine Uptake Inhibitors;	2004
Linezolid-bupropion interaction as possible etiology of severe intermittent intraoperative hypertension? Anesthesiology, 2004, Volume: 101, Issue:6 Topics: Acetamides; Anti-Infective Agents; Bupropion; Dopamine Uptake Inhibitors; Humans; Hypertension; Intr	2004
Cardiovascular effects of bupropion in depressed patients with heart disease. The American journal of psychiatry, 1991, Volume: 148, Issue:4 Topics: Aged; Aged, 80 and over; Antidepressive Agents; Blood Pressure; Bupropion; Cardiovascular System; De	1991

bupropion and Blood Pressure, High